Skip to Content

Stacy L. Moulder, M.D., M.S.C.I.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Early Drug Development
  • Clinical Trial Design
  • Determining Pathways of Drug Resistance in Breast Cancer

Click here for the most up-to-date list of Dr. Moulder's publications.

Office Address

The University of Texas MD Anderson Cancer Center
Breast Medical Oncology
1515 Holcombe Blvd.
Unit Number: 1354
Houston, TX 77030
Phone: 713-792-2817
Fax: 713-794-4385

Education & Training

Degree-Granting Education

2002 Vanderbilt University, Nashville, TN, MS, Masters of Science in Clinical Investigation
1995 University of Mississippi School of Medicine, Jackson, MS, MD, Medicine
1990 Mississippi State University, Jackson, MS, BS, Graduated Cum Laude, Chemistry

Postgraduate Training

7/1998-6/2001 Clinical Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
7/1995-6/1998 Internship and Residency, Internal Medicine, University of Mississippi Medical Center, Jackson, MS

Board Certifications

11/2002 American Board of Internal Medicine, Medical Oncology
8/1998 American Board of Internal Medicine


Administrative Appointments/Responsibilities

Chief, Section of Clinical Research and Drug Development, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2014-present

Honors and Awards

2002 Career Development Award, American Society of Clinical Oncology
2001 Fellowship Award, American Association for Cancer Research
2001 Merit Award, American Society of Clinical Oncology
2001 Star Fellow Award, Vanderbilt Hematology Oncology
2001 Trainee Travel Award, American Society of Clinical Investigation
2000 Star Fellow Award, Vanderbilt Hematology Oncology
1998-2002 Harry Joyce Fellowship, Vanderbilt University Medical Center
1994 Associated Student Body Vice President, University of Mississippi School of Medicine
1992 Medical Student Research Fellowship, University of Mississippi Medical Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. e-Pub 9/8/2015. PMID: 26348887.
2. Hatzis C, Symmans WF, Zhang Y, Gould R, Moulder S, Hunt KK, Abu-Khalaf MM, Hofstatter E, Lannin DR, Chagpar AB, Pusztai L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast cancer. Clin Cancer Res. e-Pub 8/18/2015. PMID: 26286912.
3. Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat 152(2):347-56, 7/2015. e-Pub 6/25/2015. PMCID: PMC4491106.
4. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. e-Pub 5/7/2015. PMID: 25947565.
5. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. e-Pub 5/7/2015. PMID: 25973541.
6. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 61(3):544-53, 3/2015. e-Pub 1/27/2015. PMID: 25626406.
7. Abouharb S, Moulder S. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy. Curr Oncol Rep 17(3):431, 3/2015. PMID: 25691085.
8. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. e-Pub 2/24/2015. PMID: 25712686.
9. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2/2015. e-Pub 10/18/2014. PMCID: PMC4297242.
10. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2(6):576-80, 2015. e-Pub 6/30/2015. PMCID: PMC4506360.
11. Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer 15(1):442, 2015. e-Pub 5/29/2015. PMCID: PMC4446801.
12. de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clin Breast Cancer 14(6):468-74, 12/2014. e-Pub 6/23/2014. PMCID: PMC4375949.
13. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Mol Cancer Ther 13(12):3175-84, 12/2014. e-Pub 9/24/2014. PMCID: PMC4258414.
14. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer. Clin Cancer Res 20(20):5265-71, 10/15/2014. e-Pub 8/29/2014. PMID: 25172932.
15. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 8/2014. e-Pub 7/20/2014. PMID: 25038877.
16. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 7/15/2014. e-Pub 4/17/2014. PMID: 24752867.
17. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 7/1/2014. e-Pub 3/26/2014. PMID: 24677057.
18. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 6/2014. e-Pub 3/2014. PMCID: PMC4037860.
19. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 5/30/2014. PMCID: PMC4102789.
20. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 5/15/2014. e-Pub 5/2014. PMCID: PMC4058010.
21. Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. Oncologist 19(5):453-8, 5/2014. e-Pub 4/7/2014. PMCID: PMC4012963.
22. Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer 120(6):894-900, 3/15/2014. e-Pub 11/20/2013. PMCID: PMC4128181.
23. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 3/2014. e-Pub 1/17/2014. PMCID: PMC4148903.
24. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep 6(2):377-87, 1/30/2014. e-Pub 1/16/2014. PMID: 24440717.
25. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clin Cancer Res 19(19):5474-84, 10/1/2013. PMCID: PMC3935482.
26. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 10/2013. e-Pub 8/2/2013. PMCID: PMC3809091.
27. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. Clin Cancer Res 19(17):4824-31, 9/1/2013. e-Pub 7/19/2013. PMCID: PMC3935614.
28. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 31(4):918-26, 8/2013. e-Pub 11/20/2012. PMID: 23179336.
29. Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol 31(20):e360-3, 7/10/2013. e-Pub 6/3/2013. PMID: 23733774.
30. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 1/2013. e-Pub 12/15/2012. PMCID: PMC3867793.
31. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 1/2013. e-Pub 9/28/2012. PMCID: PMC3536885.
32. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget 3(12):1566-75, 12/2012. PMCID: PMC3681495.
33. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I Study of the Anti-Angiogenic Antibody Bevacizumab and the mTOR / Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin. Clin Cancer Res 18(20):5796-805, 10/15/2012. e-Pub 8/27/2012. PMID: 22927482.
34. Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs 30(5):1942-9, 10/2012. e-Pub 9/20/2011. PMID: 21931969.
35. Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol 23 Suppl 10:x231-6, 9/2012. PMID: 22987968.
36. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 5/1/2012. e-Pub 10/17/2011. PMCID: PMC3893000.
37. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 18(10):2922-9, 5/15/2012. e-Pub 3/27/2012. PMID: 22452943.
38. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. J Clin Oncol 30(8):777-82, 3/10/2012. e-Pub 1/23/2012. PMCID: PMC3295566.
39. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11(2):308-16, 2/2012. e-Pub 12/2011. PMID: 22203732.
40. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder SL, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal Doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840-6, 11/2011. e-Pub 9/2011. PMCID: PMC3207033.
41. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128(3):783-94, 8/2011. e-Pub 6/2011. PMID: 21655990.
42. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel in Cancer Patients with Predominant Hepatic Metastases: Toxicity, Pharmacokinetics, and Activity. Mol Cancer Ther 10(7):1300-7, 7/2011. e-Pub 5/2011. PMID: 21571911.
43. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. J Clin Oncol 29(19):e572-5, 7/2011. e-Pub 4/2011. PMID: 21482991.
44. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 3/2011. e-Pub 1/2011. PMCID: PMC3072168.
45. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 10(1):209-17, 1/2011. PMID: 21220503.
46. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 11/2010. e-Pub 3/2010. PMCID: PMC3410638.
47. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28(5):634-40, 10/2010. e-Pub 6/2009. PMID: 19499186.
48. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-7, 5/2010. e-Pub 4/2010. PMID: 20423993.
49. Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 119(3):663-71, 2/2010. PMCID: PMC3133687.
50. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2/2010. PMCID: PMC3806193.
51. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 10(1):46-51, 2/2010. PMID: 20133258.
52. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin e can bypass letrozole-induced g1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16(4):1179-90, 2/2010. e-Pub 2/2010. PMCID: PMC2822889.

Invited Articles

1. Moulder SL. Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer 10:S66-71, 11/2010. PMID: 21115424.
2. Moulder SL. Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer 10:S66-71, 11/2010. PMID: 21115424.
3. Moulder SL. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 6(6):821-30, 11/2010. PMID: 21118040.
4. Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 6(6):821-30, 11/2010. PMID: 21118040.
5. Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 10:S30-40, 9/2010. PMID: 20805063.

Grant & Contract Support

Title: A Randomized Clinical Trial Platform with Translational Studies to Overcome Resistance in Triple Negative Breast Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: William F. Symmans
Duration: 6/15/2015 - 5/31/2020
Title: Southwest Early Clinical Trials (SECT) Consortium
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Funda Meric-Bernstam
Duration: 2/1/2014 - 1/31/2019
Title: Validation and implementation of genomic testing for chemotherapy and endocrine sensitivity
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator
Principal Investigator: William Symmans
Duration: 12/1/2012 - 11/30/2012
Title: LMW-E, A Novel Indicator of Letrozole Resistance in Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator
Principal Investigator: Khandan Keyomarsi
Duration: 8/1/2010 - 7/31/2014
Title: Proposal for a partnership between the Translational Breast Cancer Research Consortium and the Susan G. Komen for the Cure foundation
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 4/30/2009 - 6/30/2015

Last updated: 9/4/2015